Population pharmacokinetics of daptomycin

Antimicrobial Agents and Chemotherapy

Volumn 48, Issue 8, 2004, Pages 2799-2807

  Dvorchik, Barry ^a,c   Arbeit, Robert D ^a,d   Chung, Julia ^b   Liu, Susan ^b   Knebel, William ^b   Kastrissios, Helen ^b  

^a CUBIST PHARMACEUTICALS INC   (United States)

^b ICON Development Solutions   (United States)

^c Barry Dvorchik and Associates Inc   (United States)

^d Transcept Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DAPTOMYCIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BACTERIAL INFECTION; BODY TEMPERATURE; BODY WEIGHT; CLINICAL PHARMACOLOGY; CLINICAL TRIAL; COMPARTMENT MODEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG HALF LIFE; FEMALE; GRAM POSITIVE BACTERIUM; HEMODIALYSIS PATIENT; HUMAN; INDIVIDUALIZATION; MAJOR CLINICAL STUDY; MALE; PLASMA CLEARANCE; PRIORITY JOURNAL; SEX; STREPTOCOCCUS PNEUMONIAE;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ALGORITHMS; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; BAYES THEOREM; BODY SURFACE AREA; BODY WEIGHT; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DAPTOMYCIN; FEMALE; HALF-LIFE; HUMANS; MALE; MASS SPECTROMETRY; MIDDLE AGED; MODELS, BIOLOGICAL; MULTIPLE ORGAN FAILURE; POPULATION; SEX FACTORS;

EID: 3342894659     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.48.8.2799-2807.2004     Document Type: Article

References (20)

1. Arbeit, R. D., D. Maki, F. P. Tally, E. Campanaro, B. I. Eisenstein, and the Daptomycin 98-01 and 99-01 Investigators. 2004. The safety and efficacy of daptomycin in the treatment of complicated skin and skin structure infections. Clin. Infect. Dis. 1673-1681.
2. Beal, S. L., and L. B. Sheiner (ed.). 1988-1998. NONMEM users guides. Parts I to VIII. GloboMax LLC, Hanover, Md.
3. Brater, D. C., and P. Chennavasin. 1984. Effects of renal disease: pharmacokinetic considerations, p. 119-148. In L. Z. Benet, N. Massoud, and J. G. Gambertoglio (ed.), Pharmacokinetic basis for drug treatment. Raven Press, New York, N.Y.
4. Bush, L. M., J. A. Boscia, M. Wendeler, P. G. Pitsakis, and D. Kaye. 1989. In vitro postantibiotic effect of daptomycin (L146032) against Enterococcus faecalis and methicillin-susceptible and methicillin-resistant Staphylococcus aureus strains. Antimicrob. Agents Chemother. 33:1198-1200.
5. Canepari, P., M. Boaretti, M. Marlleo, and G. Satta. 1990. Lipoteichoic acid as a new target for activity of antibiotics. Antimicrob. Agents Chemother. 34:1220-1226.
6. Cockcroft, D. W., and M. H. Gault. 1976. Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41.
7. Critchley, I. A., D. C. Draghi, D. F. Sahm, C. Thornsberry, M. E. Jones, and J. A. Karlowsky. 2003. Activity of daptomycin against susceptible and multidrug resistant gram-positive pathogens collected in the SECURE study (Europe) during 2000-2001. J. Antimicrob. Chemother. 51:639-649.
8. Dvorcbik, B. H., D. Brazier, M. F. DeBruin, and R. D. Arbeit. 2003. Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects. Antimicrob. Agents Chemother. 47:1318-1323.
9. Fuchs, P. C., A. L. Barry, and S. D. Brown. 2002. In vitro bactericidal activity of daptomycin against staphylococci. J. Antimicrob. Chemother. 49:467-470.
10. Gibaldi, M., and D. Perrier. 1982. Pharmacokinetics, 2nd ed. Marcel Dekker, Inc., New York, N.Y.
11. 2+ and albumin on these drugs. Antimicrob. Agents Chemother. 35:1710-1716.
12. Louie, A., P. Kaw, W. Liu, N. Jumbe, M. H. Miller, and G. L. Drusano. 2001. Pharmacodynamics of daptomycin in a murine thigh model of Staphylococcus aureus infection. Antimicrob. Agents Chemother. 45:845-851.
13. Mackichan, J. J. 1992. Influence of protein binding and use of unbound free drug concentrations, p. 5-48. In W. E. Evans, J. J. Schentag, and W. J. Jusko (ed.), Applied pharmacokinetics-principles of therapeutic drug monitoring, 3rd ed. Applied Therapeutics Inc., Vancouver, Canada.
14. Mandema, J. W., D. Verotta, and L. B. Sheiner. 1992. Building population pharmacokinetic-pharmacodynamic models. I. Models for covariate effects. J. Pharmacokinet. Biopharm. 20:511-528.
15. Rowland, M., and T. N. Tozer. 1995. Clinical pharmacokinetics: concepts and applications, 3rd ed. Williams and Wilkins, Baltimore, Md.
16. Sheiner, L. B., B. Rosenberg, and V. V. Marathe. 1977. Estimation of population characteristics of pharmacokinetic parameters from routine clinical data. J. Pharmacokinet. Biopharm. 5:445-479.
17. Silverman, J. A., N. Oliver, T. Andrew, and T. Li. 2001. Resistance studies with daptomycin. Antimicrob. Agents Chemother. 45:1799-1802.
18. Wesson, K. M., D. S. Lerner, N. B. Silverberg, and J. M. Weinberg. 2003. Linezolid, quinupristin/dalfopristin and daptomycin in dermatology. Clin. Dermatol. 21:64-69.
19. Wise, R., T. Gee, J. M. Andrews, B. Dvorchik, and G. Marshall. 2002. Pharmacokinetic and inflammatory fluid penetration of intravenous daptomycin in volunteers. Antimicrob. Agents Chemother. 46:31-33.
20. Woodworth, J. R., E. H. Nyhart, G. L. Brier, J. D. Wolny, and H. R. Black. 1992. Single-dose pharmacokinetics and antibacterial activity of daptomycin, a new lipopeptide antibiotic, in healthy subjects. Antimicrob. Agents Chemother. 36:318-325.